Clinical trials: Depressive Disorder NOS
Health Attitude, Knowledge, Attitudes, Practice
Development and Pilot Test of a Postnatal mHealth Intervention - Phase 2
The goal of the study is to assess the feasibility and acceptability of the optimized MeSSSSage intervention which was developed and revised based on the results of our initial pilot testing.
- Conditions
- Health Attitude, Knowledge, Attitudes, Practice, Post Partum Depression, Acceptability of Health Care
- Trial name
- MESSAGE (NCT04693585)
- Testing
- MESSSSAGE - live, MESSSSAGE - asynchronous
- Where
- India
- Volunteers
- 201 people
- Sponsor
- University of California, San Francisco
Schizophrenia, Schizoaffective Disorder
Get Moving and Get Well - Pilot Study
Individuals with serious mental illness have greater morbidity from physical illness and mortality than the general population, but tend not to initiate or sustain engagement in health promotion interventions.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
- Trial name
- GMGWP (NCT01884025)
- Testing
- Get Moving and Get Well, Health and Humor Class
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of…
- Trial name
- NCT00608543
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder, Back Pain
Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults
The following primary hypotheses will be tested: 1. During Step 1: Major Depressive Disorder (MDD) or Chronic Low Back Pain (CLBP) in < 40% of the initial 60 subjects treated with duloxetine (DUL) + Clinical Management(CM) during…
- Conditions
- Major Depressive Disorder, Back Pain, Aged
- Trial name
- ACHIEVE2 (NCT00696293)
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Adjunctive Treatment of Major Depressive Disorder
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.
- Trial name
- NCT04000009
- Testing
- Pimavanserin
- Where
- 71 sites in United States, Finland and 7 more
- Volunteers
- 235 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate the efficacy, tolerability and the safety of two fixed doses of vortioxetine in the treatment of major depressive disorder.
- Trial name
- NCT01140906
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 607 people
- Sponsor
- H. Lundbeck A/S
Depression
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT01204918
- Testing
- Riluzole
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Sleep-disordered Breathing, Major Depressive Disorder
Sleep-Disordered Breathing and PAP in Perinatal Depression
The goal of this study is to understand the contribution of sleep-disordered breathing (SDB) to one of the most common and debilitating adverse pregnancy outcomes, perinatal depression.
- Trial name
- NCT02507297
- Testing
- Positive Airway Pressure (PAP)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Binge Eating, Depression
Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression
The purpose of this research study is to test the safety of duloxetine and see what effects (good and bad) it has on the subject's binge eating disorder and comorbid depressive disorder (depression occurring with binge eating…
- Trial name
- NCT00607789
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Major Depressive Disorder
Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
- Trial name
- NCT00854100
- Testing
- Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
- Where
- 41 sites in United States
- Volunteers
- 231 people
- Sponsor
- Forest Laboratories
Schizophrenia, Major Depression
Past Pain Experience and Perception of Experimental Pain
Differences in pain perception between subjects with and without psychiatric illness may be influenced by the individual experience, and not primarily by the pathology, although the pathological frame may amplify it.The aim of…
- Trial name
- NCT01575912
- Testing
- experimental pain tests
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Esquirol
Major Depressive Disorder
Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy
In this Phase 4 trial we will study the safety, tolerability and efficacy of mixed salts amphetamine (MSA), trade name Adderall, augmentation of antidepressant therapy for Major Depressive Disorder (MDD) in depressed outpatient…
- Trial name
- NCT02058693
- Testing
- mixed salts amphetamine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Rush University Medical Center
Major Depressive Disorder
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders…
- Trial name
- NCT05061706
- Testing
- Lumateperone
- Where
- 50 sites in United States, Argentina and 5 more
- Volunteers
- 480 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder (MDD)
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
The purpose of this study is to assess if LY2216684 (flexible dose of 12 to 18 milligrams [mg] or fixed dose of 6 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with Major Depressive…
- Trial name
- NCT01187407
- Testing
- LY2216684, SSRI
- Where
- 54 sites in United States, Croatia and 5 more
- Volunteers
- 1,480 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained release (DVS SR) or placebo for 12 weeks.
- Trial name
- NCT00824291
- Testing
- desvenlafaxine succinate sustained release, Genotyping
- Volunteers
- 437 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Modeling Multi-level Dyadic Behavior to Transform the Science and Practice of Psychotherapy Process and Outcome.
This is a short-term longitudinal study of psychotherapy process. Participants will be treated with 8 sessions of psychotherapy over the course of 8 to 12 weeks.
- Trial name
- DAPPeR (NCT03594773)
- Testing
- Cognitive Behavioral Therapy, Interpersonal Psychotherapy
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers utilizing a slow-infusion intravenous (IV) route of administration.
- Trial name
- NCT04711005
- Testing
- (2R,6R)-Hydroxynorketamine hydrochloride
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
Neuroimaging in Patients Undergoing TMS for Depression
The goal of this project is to guide rTMS using functional magnetic resonance imaging (fMRI) in individuals with depression who did not respond to standard TMS treatment to evaluate whether targeted TMS using individualized…
- Trial name
- NIPUTFD (NCT02974296)
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- New York State Psychiatric Institute
Postpartum Depression
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the…
- Trial name
- NCT02978326
- Testing
- SAGE-217 15/20 mg Oral Solution, SAGE 217 30 mg Capsules
- Where
- 27 sites in United States
- Volunteers
- 276 people
- Sponsor
- Biogen